Viking Global Investors LP sold $11M of INBX
owner at Inhibrx Biosciences, Inc.. 350,000 shares at an average of $32.25, traded Oct 7, 2025, filed Oct 9, 2025.
Score components
- +12Role10% owner
- +25Trade size$11.3M at market
- +5Share of holdings soldSold 22% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +130.5%, 3m +114.9%, 6m +116.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000905148-25-003555, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 7, 2025 | SOpen-market sale Common Stockindirect: See Explanation of Responses | -308,643 | $32.25 | $10.0M | 1,267,823 | Oct 9, 2025 |
| Oct 7, 2025 | SOpen-market sale Common Stockindirect: See Explanation of Responses | -16,315 | $32.25 | $526k | 67,018 | Oct 9, 2025 |
| Oct 7, 2025 | SOpen-market sale Common Stockindirect: See Explanation of Responses | -25,042 | $32.25 | $808k | 102,864 | Oct 9, 2025 |
Related signals
Other insiders at Inhibrx Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 63Notable | Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $999k 10,000 shares | +1% | |
| 46Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 53Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $500k 5,000 shares | +1% | |
| 31Weak | INBXsell Inhibrx Biosciences, Inc. | Kimberly Manhard director | $164k 1,500 shares | -17% | |
| 30Weak | INBXsell Inhibrx Biosciences, Inc. | Kimberly Manhard director | $115k 1,000 shares | -10% | |
| 44Moderate | Inhibrx Biosciences, Inc. | Douglas Forsyth director | $287k 2,500 shares | +1% | |
| 65Notable | Inhibrx Biosciences, Inc. | Mark Lappe Chief Executive Officer | $2.6M 25,000 shares | +4% | |
| 49Moderate | Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $568k 5,000 shares | +1% | |
| 50Moderate | INBXbuy Inhibrx Biosciences, Inc. | Jon Faiz Kayyem director | $1.5M 107,186 shares | +660% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.